newswire, breaking biotechnology and pharma news

Tuesday, January 15, 2013

OTC Biotech/ Pharma Stocks Alert: (OTCBB:SBFM), (OTCQB:ONCS), (OTCQB:XXII), (OTCQB:LJPC)

Point Roberts, WA - January 15, 2013 ( Newswire), an investor research portal specializing in sector research including biotech and pharma stocks, issues an alert for investors following stocks in the small and microcap markets. Recent news from Sunshine Biopharma Inc. (OTCBB: SBFM), OncoSec Medical Inc. (OTCQB: ONCS), 22nd Century Group, Inc. (OTCQB/OTCBB: XXII) and (OTCQB: LJPC) has made headlines in yesterday's and today's trading session.

Sunshine Biopharma Inc. (OTCBB: SBFM) reported today that its parent company, Advanomics Corporation, has just filed in the United States a new patent application covering various manufacturing methodology and molecular aspects of Adva-27a. Advanomics intends to expand this new Adva-27a protection worldwide by filing appropriate international patent applications within the prescribed time limits from this initial filing. Advanomics has recently completed acquisition of the original Adva-27a worldwide patents filed in April 2007 from Institut National des Sciences Appliquees, a government research lab in France. If granted, this new patent filing will extend Adva-27a exclusivity by nearly six years, from April 2027 to January 2033.
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells as well as other aggressive cancer cells in vitro (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original US patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
"Having an upgraded patent position is extremely important in the drug business", said Dr. Steve N. Slilaty, Sunshine Biopharma's CEO. "Coverage of the new molecular aspects of Adva-27a and the approximately six additional years of protection factor significantly into the Company's financial equations", he added.
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, reported the company's upcoming milestones for 2013 at the Biotech Showcase conference held January 7-9 in San Francisco, CA.
OncoSec Medical Incorporated (ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics.
22nd Century Group, Inc. (OTCQB/OTCBB: XXII) reported that it closed a private placement on Friday, January 11, 2013 with an institutional investor. 22nd Century sold 2500 shares of its Series A convertible preferred stock and a 5-year warrant for an aggregate purchase price of $2.5 million. 22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding.
La Jolla Pharmaceutical Company (OTCQB: LJPC ) a company in the development of therapeutics that target galectin-3, announced that it has recently made two additions to its management team.
About is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow on Twitter!/Investorideas
Follow on Facebook
Follow News on at
Sign up for the free investor news and stock alerts at including biotech stocks:
Research more biotech stocks at biotech stock directory of TSX, OTC, NASDAQ and NYSE stocks :
Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SBFM is an expired news publication and content client on . was previously compensated and is long SBFM shares. More info : Investorideas was not compensated for this release. BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
800-665-0411 - Source -

No comments:

Post a Comment